Table 1.

Characteristics of the study‚ÄČpopulation

PatientAntiretroviral therapyaAge (mo)Baseline plasma RNA (log copies/ml)Baseline % CD4Time (wk) to RNA <400Length of follow-up (mo)
P-1048ZDV/3TC/NVP0.54.5341229
P-1216ZDV/3TC/NVP2.85.7141227
P-1228ZDV/3TC/NVP1.15.3471632
P-1232ZDV/3TC/NVP/ABV3.05.0401621
P-1235ZDV/3TC/NVP/ABV2.25.324227
P-1238ZDV/3TC/NVP/ABV3.03.3520.524
P-1246ZDV/3TC/NVP/ABV0.85.254824
P-1247ZDV/3TC/NVP/ABV1.14.363421
P-1222d4T/3TC/NVP/NLF1.85.5361618
P-1223d4T/3TC/NVP/NLF1.55.234818
P-1231d4T/3TC/NVP/NLF1.75.8521616
P-1233d4T/3TC/NVP/NLF1.95.6301216
P-1251d4T/3TC/NVP/NLF2.25.219818
P-1252d4T/3TC/NVP/NLF1.65.446818
P-1260d4T/3TC/NVP/NLF2.45.2551218
P-3743ZDV/ddI/NVP2.55.544856
P-3742ZDV/ddI/NVP2.55.5572056
  • a ABV, abacavir.